Wind farm giant Orsted's chief executive quits
Mads Nipper will leave the Danish company after a series of vast writedowns and declining share prices in recent years.
Rasmus Errboe, his deputy, will take the top job on Saturday, the company said in a statement.
Orsted is developing the largest offshore wind farm in the world about 75 miles off the Norfolk coast in the North Sea.
Hornsea 3 is expected to be completed in late 2027, and will sit alongside 12 other wind farms either developed or part-developed by Orsted in the UK.
Between them, they can already generate enough electricity to power about six million homes.
But while the UK is pushing ahead with plans to develop wind farms as part of a push to reach net zero in the power system by 2030, the situation is more complicated in other countries.
The US, in particular, is a significant doubt for Orsted, after President Donald Trump said he would stop federal permission for new offshore wind projects.
The company took a 1.7 billion dollar hit on a project in the country earlier this month, amid rising costs to develop one of its wind farms.
'The impacts on our business of the increasingly challenging situation in the offshore wind industry, ranging from supply chain bottlenecks, interest rate increases, to a changing regulatory landscape, mean that our focus has shifted,' said Lene Skole, the company's chair.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Barcelona sporting director sends clear message to defensive outcast
Barcelona are facing a race against time as they look to not only register the new signings but also get the Camp Nou prepared for September matches. In the midst of all that, the club are facing a financial crunch once again and desperately require fresh sales in order to balance the books and return to the 1:1. Following the departures of Pablo Torre, Pau Victor and Ansu Fati, the next player in line to leave Barcelona this summer is Andreas Christensen. But the Dane, despite being considered a benchwarmer, has appeared hesitant to leave Barcelona. Deco's clear message to Christensen According to Diario SPORT, Barcelona, led by sporting director Deco, has sent a clear message to Christensen: renewal is off the table, and the door is open if he chooses to leave. Deco has already tied down most of the squad to long-term contracts as part of his ongoing renewal project. Jules Kounde, Eric Garcia, and even Frenkie de Jong are set for new extensions next week. The only outlier is Christensen, whose deal expires in 2026, with no extension talks planned. Andreas Christensen has no intention to leave (Photo by) Barcelona are reportedly open to selling the Danish international, who is on a relatively high salary and spent much of last season injured. With an overbooking of centre-backs in the squad, Deco is focused on trimming the wage bill and building a younger, more sustainable core. However, the 28-year-old has no intention of walking away. Much like his exit from Chelsea, Christensen is prepared to stay until the end of his contract. Despite interest from Saudi Arabia and the Premier League, he has refused to even engage in negotiations. Convincing the Dane, therefore, will be one of Deco's priorities in the month of August.
Yahoo
3 days ago
- Yahoo
Novo Nordisk shares dip further as Wegovy gains nearly erased
By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
3 days ago
- Bloomberg
Novo Nordisk Loses Spot Among Europe's 10 Most Valuable Firms
By Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe's most valuable public company again. Now, the stock — which is set for its worst week on record — is out of the top ten. The shares have plunged 33% this week after the maker of Ozempic and Wegovy cut its forecasts for the year and named a company insider as its new chief executive officer. The stock was also hit on Friday after US President Donald Trump demanded that pharmaceutical companies lower US drug prices.
